查看文章

Recent announcements indicated, without sharing any distinct published set of results, that use of the corticosteroid dexamethasone in a large trial in the UK apparently reduced mortality of only severe, intubated, COVID-19 patients by about 30%(1). It is obviously important to await the publication of the complete set of results, as well as the subsequent course of the patients enrolled. The recent Coronavirus [severe acute respiratory syndrome (SARS)-CoV-2]-associated multiorgan disease, called COVID-19 (2), has high morbidity and mortality due to autoimmune destruction of the